Exotic varieties of maize are collected to add genetic diversity when selectively breeding new domestic strains

Mexican Supreme Court Refuses to Review Monsanto Appeal on GMO Maize Permits

The first chamber of the Mexican Supreme Court of Justice of the Nation (SCJN) has refused to review or analyze an appeal by Monsanto regarding the issuance of commercial permits for the sowing of GMO maize in the country.

May 12, 2017 | Source: Sustainable Pulse | by

The first chamber of the Mexican Supreme Court of Justice of the Nation (SCJN) has refused to review or analyze an appeal by Monsanto regarding the issuance of commercial permits for the sowing of GMO maize in the country.

In this way, the decision to resolve the GMO trials involving the companies Monsanto, Dow, Pioneer and Dupont, as well as the Mexican Government Departments of the Environment and Agriculture, and on the other side, civil society and academic organizations that are opposed to the sowing of GMO maize, will have to be resolved by the First Collegiate Court on Civil Matters.

This review case began last January, when the Collegial Court was about to issue a ruling on whether to maintain the precautionary measure imposed in September 2013, which banned the authorizations for GMO maize plantings pending resolution of the problem. On January 26, the Court suspended the vote on the resolution because Monsanto submitted a petition to the SCJN.

The lawyer of the civil society Corn Collective, René Sánchez Galindo, explained that last Wednesday in a private meeting, the Supreme Court judges evaluated the appeal that Monsanto filed. None of the judges endorsed the company’s request, which was a requirement for the Court to place the appeal on its docket.

Galindo considered that the arguments of the company—that transgenic maize is not harmful to health and the environment—are repetitive and reiterate what the companies Dow, Pioneer and Dupont said in another 22 lawsuits. He recalled that the Appeals Court ruled, inter alia, that the benefits of GMOs are uncertain. This decision was not contested by the Biotech companies, which have not been able to show the economic benefit of GMOs.